8-K: CeriBell Appoints Medtech Veteran Erica Rogers to Board

CeriBell, Inc. announced the appointment of Erica Rogers, a seasoned medtech executive, to its Board of Directors and Compensation Committee, effective September 17, 2025.

Summary

• CeriBell, Inc. appointed Erica Rogers to its Board of Directors and Compensation Committee, effective September 17, 2025.
• Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies.
• She previously served as Chief Executive Officer of Silk Road Medical, Inc., where she led the company from a 25-person startup to a 500-employee publicly-traded company with revenue exceeding $175 million, culminating in its acquisition by Boston Scientific Corporation.
• Ms. Rogers will receive annual cash compensation and restricted stock units in accordance with the company's Non-Employee Director Compensation Program and will enter into an indemnification agreement.
• Ceribell's CEO, Jane Chao, highlighted Ms. Rogers' experience in scaling healthcare companies and driving adoption of new technologies as invaluable for expanding nationwide access to their point-of-care EEG system.
• Ms. Rogers expressed enthusiasm for supporting Ceribell's efforts to broaden access to its rapid EEG technology, which has already improved care for hundreds of thousands of critically ill patients in over 550 hospitals.

Sentiment

Score: 8

Explanation: The appointment of Erica Rogers, a highly accomplished and experienced medtech executive, to the Board of Directors is a significant positive development. Her proven track record in scaling companies, driving commercial expansion, and navigating the regulatory landscape is a strong endorsement of Ceribell's growth potential and strategic direction. This move is expected to enhance governance and accelerate market penetration for Ceribell's innovative EEG system.

Positives

• Appointment of Erica Rogers, an accomplished healthcare executive with over three decades of experience in leading high-growth medical device companies.
• Ms. Rogers' proven track record includes scaling Silk Road Medical from a 25-person startup to a 500-employee public company with over $175 million in revenue, leading to its acquisition by Boston Scientific.
• Her expertise in driving adoption of new technologies in clinical practice is expected to be invaluable as Ceribell expands nationwide access to its point-of-care EEG system.
• Ceribell's rapid EEG technology has already improved care for hundreds of thousands of critically ill patients in more than 550 hospitals.
• The appointment strengthens the Board's strategic leadership and expertise in scaling innovative medical technology.

Risks

• Risks and uncertainties that could cause actual results to differ materially from forward-looking statements are described under the Risk Factors sections of the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the U.S. Securities and Exchange Commission (SEC).

Future Outlook

Forward-looking statements are based on management's current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. The company undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Management Comments

• "We welcome Erica at a pivotal growth phase for Ceribell, as we expand nationwide access to our point-of-care EEG system to help clinicians deliver timely care for critically ill patients." Jane Chao, PhD, Co-founder and CEO of Ceribell.
• "Her experience in scaling healthcare companies and driving adoption of new technologies in clinical practice will be invaluable as we work to establish the Ceribell System as the standard of care." Jane Chao, PhD, Co-founder and CEO of Ceribell.
• "Ceribell is pioneering a new era of timely brain monitoring, positively transforming patient outcomes." Erica Rogers.
• "The impact of its groundbreaking rapid EEG technology has already improved care for hundreds of thousands of critically ill patients in more than 550 hospitals." Erica Rogers.
• "I look forward to supporting its ongoing efforts to broaden access to this significant advancement in healthcare." Erica Rogers.

Industry Context

The appointment of a highly experienced medtech executive like Erica Rogers underscores Ceribell's strategic focus on scaling its innovative point-of-care EEG system within the competitive medical device industry. Her background in leading companies through FDA approval, commercial expansion, and ultimately acquisition by a major player like Boston Scientific, positions Ceribell to navigate market challenges and accelerate the adoption of its technology as a standard of care for neurological conditions, aligning with broader trends towards rapid, accessible diagnostic tools in acute care.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Expected to benefit from enhanced strategic guidance, improved corporate governance, and accelerated growth potential due to Ms. Rogers' expertise in scaling medtech companies and driving market adoption.
• Employees: Will benefit from stronger leadership and strategic direction, potentially leading to clearer company objectives and growth opportunities.
• Customers (Hospitals/Clinicians): Expected to see continued expansion of access to the Ceribell System, potentially leading to improved patient care and diagnostic capabilities.
• Patients: Anticipated to benefit from broader access to timely brain monitoring and improved outcomes for serious neurological conditions.

Next Steps

• Ms. Rogers will serve as a director until the company's next annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier resignation or removal.
• Ceribell will continue its efforts to expand nationwide access to its point-of-care EEG system and establish it as the standard of care.

Key Dates

Recommendation

The appointment of Erica Rogers is a highly positive strategic move for Ceribell. Her extensive experience in successfully scaling medical device companies, including leading Silk Road Medical to a significant acquisition, provides a strong signal of Ceribell's growth ambitions and potential. Her expertise in commercial expansion and technology adoption is directly relevant to Ceribell's mission to establish its EEG system as the standard of care. This addition to the board significantly strengthens the company's leadership and strategic capabilities, making it a compelling 'strong buy' for investors looking for growth in the medtech sector.

Keywords

CeriBell, CBLL, Erica Rogers, Board of Directors, Medtech, Medical Device, EEG, Neurological Conditions, Healthcare Technology, Corporate Governance, Executive Appointment, Silk Road Medical, Boston Scientific